Novartis expands biopharmaceutical plant in Slovenia
This article was originally published in Scrip
Executive Summary
Sandoz, Novartis's generics arm, has opened a new $3.8 million, 430m2 production facility at the premises of Sandoz Slovenia (formerly Lek) in Menges, which will make modified proteins, including the epoetin alfa active ingredient. The site is one of Sandoz's three main biopharmaceutical development and production centres.